Hyperfine (HYPR) Cash from Investing Activities (QoQ) (2021 - 2026)
Hyperfine (HYPR) Cash from Investing Activities (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Hyperfine | 94.51 Mn | 53.23 Mn | 1.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -284.13% |
| Dec 31, 2025 | 51.54% |
| Sep 30, 2025 | 75.00% |
| Jun 30, 2025 | -10.17% |
| Mar 31, 2025 | -5,800.00% |
| Dec 31, 2024 | 94.97% |
| Sep 30, 2024 | -123.94% |
| Jun 30, 2024 | 51.03% |
| Mar 31, 2024 | 43.80% |
| Dec 31, 2023 | 1.90% |
| Sep 30, 2023 | -18.47% |
| Jun 30, 2023 | -263.93% |
| Mar 31, 2023 | 61.39% |
| Dec 31, 2022 | 8.67% |
| Sep 30, 2022 | -420.37% |
| Jun 30, 2022 | 117.53% |
| Mar 31, 2022 | 68.41% |
| Dec 31, 2021 | 8.11% |
| Sep 30, 2021 | -110.10% |
| Jun 30, 2021 | -197.06% |